Chronic treatment with serotonin reuptake inhibitor antidepressant (SSRI) combined with an antipsychotic regulates GABA-A receptor in rat prefrontal cortex

Psychopharmacology

Volumn 220, Issue 4, 2012, Pages 763-770

  Danovich, Lena ^a   Weinreb, Orly ^a   Youdim, Moussa B H ^a   Silver, Henry ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

GABA A receptor; Fluvoxamine; Haloperidol; Schizophrenia; Signaling pathways

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR BETA2; 4 AMINOBUTYRIC ACID A RECEPTOR BETA3; CLOZAPINE; FLUVOXAMINE; HALOPERIDOL; MITOGEN ACTIVATED PROTEIN KINASE 1; MUSCIMOL; PROTEIN KINASE C; 4 AMINOBUTYRIC ACID A RECEPTOR; ANTIDEPRESSANT AGENT; NEUROLEPTIC AGENT; SEROTONIN UPTAKE INHIBITOR;

ADULT; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOSOL; DRUG MECHANISM; ENZYME PHOSPHORYLATION; LONG TERM CARE; MALE; MONOTHERAPY; NERVE CELL MEMBRANE; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TRANSPORT; RAT; RECEPTOR DOWN REGULATION; RIGHTING REFLEX; SIGNAL TRANSDUCTION; ANIMAL; COMPARATIVE STUDY; DRUG COMBINATION; DRUG EFFECT; PHYSIOLOGY; RANDOMIZATION; SPRAGUE DAWLEY RAT; TREATMENT OUTCOME;

ANIMALS; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; DRUG THERAPY, COMBINATION; MALE; PREFRONTAL CORTEX; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, GABA-A; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 84871891497     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-011-2530-y     Document Type: Article

References (44)

1. Arnsten AF (2009) Ameliorating prefrontal cortical dysfunction in mental illness: inhibition of phosphotidyl inositol-protein kinase C signaling. Psychopharmacology (Berl) 202:445-455
2. Bloch MH, Landeros-Weisenberger A, Kelmendi B., Coric V, Bracken MB, Leckman J.F. (2006) A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Mol Psychiatr 11:622-632
3. Bobo WV, Shelton R.C. (2009) Fluoxetine and olanzapine combination therapy in treatment-resistant major depression: review of efficacy and safety data. Expert Opin Pharmacother 10:2145-2159
4. Brandon NJ, Delmas P, Kittler J.T., McDonald BJ, Sieghart W, Brown DA, Smart T.G., Moss S.J. (2000) GABAA receptor phosphorylation and functional modulation in cortical neurons by a protein kinase C-dependent pathway. J Biol Chem 275:38856-38862
5. Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM (1999) Olanzapine. Pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet 37:177-193
6. Centorrino F, Baldessarini RJ, Frankenburg F.R., Kando J., Volpicelli SA, Flood J.G. (1996) Serum levels of clozapine and norclozapine in patients treated with selective serotonin reuptake inhibitors. Am J Psychiatry 153:820-822
7. Chang WH, Augustin B, Lane H.Y., ZumBrunnen T., Liu HC, Kazmi Y, Jann M.W. (1999) In-vitro and in-vivo evaluation of the drug-drug interaction between fluvoxamine and clozapine. Psycho-pharmacology (Berl) 145:91-98
8. Chertkow Y, Weinreb O, Youdim M.B., Silver H. (2006) The effect of chronic co-administration of fluvoxamine and haloperidol compared to clozapine on the GABA system in the rat frontal cortex. Int J Neuropsychopharmacol 9:287-296
9. Chertkow Y, Weinreb O, Youdim M.B., Silver H. (2009) Molecular mechanisms underlying synergistic effects of SSRI-antipsychotic augmentation in treatment of negative symptoms in schizophrenia. J Neural Transm 116:1529-1541
10. Cobos EJ, Entrena JM, Nieto F.R., Cendan CM, Del Pozo E (2008) Pharmacology and therapeutic potential of sigma(1) receptor ligands. Curr Neuropharmacol 6:344-366
11. Daniel DG, Randolph C, Jaskiw G., Handel S, Williams T, Abi-Dargham A, Shoaf S., Egan M, Elkashef A, Liboff S et al (1994) Coadministration of fluvoxamine increases serum concentrations of haloperidol. J Clin Psychopharmacol 14:340-343
12. Danovich L, Weinreb O, Youdim M.B., Silver H. (2011) The involvement of GABA(A) receptor in the molecular mechanisms of combined selective serotonin reuptake inhibitor-antipsychotic treatment. Int J Neuropsychopharmacol 14:143-155
13. Diaz FJ, Santoro V, Spina E., Cogollo M, Rivera TE, Botts S, de Leon J (2008) Estimating the size of the effects of co-medications on plasma clozapine concentrations using a model that controls for clozapine doses and confounding variables. Pharmacopsychiatry 41:81-91
14. Falkai P, Wobrock T, Lieberman J., Glenthoj B, Gattaz WF, Moller H.J. (2006) World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: long-term treatment of schizophrenia. World J Biol Psychiatr 7:5-40
15. Fumagalli F, Molteni R, Calabrese F., Frasca A, Racagni G, Riva M.A. (2005) Chronic fluoxetine administration inhibits extracellular signal-regulated kinase 1/2 phosphorylation in rat brain. J Neurochem 93:1551-1560
16. Hiemke C, Peled A, Jabarin M., Hadjez J, Weigmann H, Hartter S., Modai I, Ritsner M, Silver H (2002) Fluvoxamine augmentation of olanzapine in chronic schizophrenia: pharmacokinetic interactions and clinical effects. J Clin Psychopharmacol 22:502-506
17. Kalluri HS, Ticku M.K. (2002) Role of GABA(A) receptors in the ethanol-mediated inhibition of extracellular signal-regulated kinase. Eur J Pharmacol 451:51-54
18. Kim SH, Seo MS, Jeon W.J., Yu HS, Park HG, Jung GA, Lee H.Y., Kang UG, Kim YS (2008) Haloperidol regulates the phosphor-ylation level of the MEK-ERK-p90RSK signal pathway via protein phosphatase 2A in the rat frontal cortex. Int J Neuro-psychopharmacol 11:509-517
19. Kumar S, Khisti RT, Morrow A.L. (2005) Regulation of native GABAA receptors by PKC and protein phosphatase activity. Psychopharmacology (Berl) 183:241-247
20. Lammers CH, Deuschle M, Weigmann H., Hartter S, Hiemke C, Heese C., Heuser I. (1999) Coadministration of clozapine and fluvox-amine in psychotic patients-clinical experience. Pharmacopsy-chiatry 32:76-77
21. Lu ML, Lane HY, Chen K.P., Jann MW, Su MH, Chang W.H. (2000) Fluvoxamine reduces the clozapine dosage needed in refractory schizophrenic patients. J Clin Psychiatr 61:594-599
22. Luscher B, Fuchs T, Kilpatrick C.L. (2011) GABAA receptor trafficking-mediated plasticity of inhibitory synapses. Neuron 70:385-409
23. Marx CE, VanDoren MJ, Duncan G.E., Lieberman JA, Morrow A.L. (2003) Olanzapine and clozapine increase the GABAergic neuroactive steroid allopregnanolone in rodents. Neuropsycho-pharmacology 28:1-13
24. Monnet FP, Morin-Surun MP, Leger J., Combettes L. (2003) Protein kinase C-dependent potentiation of intracellular calcium influx by sigma1 receptor agonists in rat hippocampal neurons. J Pharmacol Exp Ther 307:705-712
25. Muir J, Arancibia-Carcamo IL, MacAskill A.F., Smith KR, Griffin LD, Kittler J.T. (2010) NMDA receptors regulate GABAA receptor lateral mobility and clustering at inhibitory synapses through serine 327 on the gamma2 subunit. Proc Natl Acad Sci U S A 107:16679-16684
26. Pereira A, Fink G, Sundram S. (2009) Clozapine-induced ERK1 and ERK2 signaling in prefrontal cortex is mediated by the EGF receptor. J Mol Neurosci 39:185-198
27. Poyurovsky M, Isakov V, Hromnikov S., Modai I, Rauchberger B, Schneidman M., Weizman A. (1999) Fluvoxamine treatment of obsessive-compulsive symptoms in schizophrenic patients: an add-on open study. Int Clin Psychopharmacol 14:95-100
28. Remington G (2003) Understanding antipsychotic "atypicality": a clinical and pharmacological moving target. J Psychiatry Neuro-sci 28:275-284
29. Rummel C, Kissling W, Leucht S. (2005) Antidepressants as add-on treatment to antipsychotics for people with schizophrenia and pronounced negative symptoms: a systematic review of randomized trials. Schizophr Res 80:85-97
30. Shelton RC (2006) The return of fixed combinations in psychiatry: fluoxetine and olanzapine combination. Ther Clin Risk Manag 2:187-192
31. Silver H (2001) Fluvoxamine as an adjunctive agent in schizophrenia. CNS Drug Rev 7:283-304
32. Silver H, Nassar A. (1992) Fluvoxamine improves negative symptoms in treated chronic schizophrenia: an add-on double-blind, placebo-controlled study. Biol Psychiatry 31:698-704
33. Silver H, Aharon N, Kaplan A. (2003a) Add-on fluvoxamine improves primary negative symptoms: evidence for specificity from response analysis of individual symptoms. Schizophr Bull 29:541-546
34. Silver H, Nassar A, Aharon N., Kaplan A. (2003b) The onset and time course of response of negative symptoms to add-on fluvoxamine treatment. Int Clin Psychopharmacol 18:87-92
35. Silver H, Susser E, Danovich L., Bilker W, Youdim M, Goldin V., Weinreb O. (2010) SSRI augmentation of antipsychotic alters expression of GABAA receptor and related genes in PMC of schizophrenia patients. Int J Neuropsychopharmacol: 1-12
36. Spina E, Avenoso A, Facciola G., Fabrazzo M, Monteleone P, Maj M., Perucca E, Caputi AP (1998) Effect of fluoxetine on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenia. Int Clin Psychopharmacol 13:141-145
37. Spina E, Avenoso A, Salemi M., Facciola G, Scordo MG, Ancione M, Madia A. (2000) Plasma concentrations of clozapine and its major metabolites during combined treatment with paroxetine or sertraline. Pharmacopsychiatry 33:213-217
38. Stieffenhofer V, Saglam H, Schmidtmann I., Silver H, Hiemke C, Konrad A. (2011) Clozapine plasma level monitoring for prediction of rehospitalization schizophrenic outpatients. Phar-macopsychiatry 44:55-59
39. Szegedi A, Anghelescu I, Wiesner J., Schlegel S, Weigmann H, Hartter S., Hiemke C, Wetzel H (1999) Addition of low-dose fluvox-amine to low-dose clozapine monotherapy in schizophrenia: drug monitoring and tolerability data from a prospective clinical trial. Pharmacopsychiatry 32:148-153
40. Ugale RR, Hirani K, Morelli M., Chopde C.T. (2004) Role of neuroactive steroid allopregnanolone in antipsychotic-like action of olanzapine in rodents. Neuropsychopharmacology 29:1597-1609
41. Wassef A, Baker J, Kochan L.D. (2003) GABA and schizophrenia: a review of basic science and clinical studies. J Clin Psychophar-macol 23:601-640
42. Wetzel H, Anghelescu I, Szegedi A., Wiesner J, Weigmann H, Harter S., Hiemke C. (1998) Pharmacokinetic interactions of clozapine with selective serotonin reuptake inhibitors: differential effects of fluvoxamine and paroxetine in a prospective study. J Clin Psychopharmacol 18:2-9
43. Zheng G, Zhang X, Chen Y., Zhang Y, Luo W, Chen J. (2007) Evidence for a role of GABAA receptor in the acute restraint stress-induced enhancement of spatial memory. Brain Res 1181:61-73
44. Zheng G, Zhang W, Zhang Y., Chen Y, Liu M, Yao T., Yang Y, Zhao F, Li J, Huang C, Luo W, Chen J (2009) gamma-Aminobutyric acid (A) (GABA(A)) receptor regulates ERK1/2 phosphorylation in rat hippocampus in high doses of methyl tert-butyl ether (MTBE)-induced impairment of spatial memory. Toxicol Appl Pharmacol 236:239-245